Human MSLN Stable Cell Line - CHO-K1

Lung cancer is a prevalent disease that kills one million people worldwide each year. The MSLN Stable Cell Line - CHO-K1 was utilized by researchers to investigate CAR-T treatment in non-small cell lung cancer (NSCLC) and mesothelioma. These second-generation CAR-T cells, which target mesothelin (MSLN), included co-stimulatory CD28 and 4-1BB signaling domains to increase proliferation. Flow cytometry validated the successful production of CAR-T cells, and cytotoxicity tests using the LDH kit proved the ability to kill target cells. In vivo investigations on a mouse model inoculated with tumor-derived cells from patients revealed that CAR-T MSLN cells dramatically inhibited tumor growth when injected into the tail vein, underscoring the potential and problems of CAR-T therapy in solid tumors.

Figure 1. The researchers utilized the MSLN Stable Cell Line - CHO-K1 to study MSLN expression, as evidenced by flow cytometry and LDH cytotoxicity assays. (Ye L, et al., 2019)